IsoPlexis launches new COVID-19 proteomics grant challenge
IsoPlexis has unveiled its Single-Cell Proteomics COVID-19 Grant Challenge, which will award 12 of the company's IsoCode or CodePlex chips to two winners for proposed projects that demonstrate research novelty and innovation using single-cell proteomics. Read More
Celltrion initiates phase I trial of COVID-19 antibody treatment
The Korean Ministry of Food and Drug Safety has approved Celltrion's investigational new drug application for a phase I clinical trial of CT-P59, a COVID-19 antiviral antibody treatment candidate. Read More
HiFiBio submits IND for SARS-CoV-2 treatment
HiFiBio Therapeutics has submitted an investigational new drug (IND) application with the U.S. Food and Drug Administration for novel SARS-CoV-2 neutralizing antibodies for the treatment of COVID-19 patients. Read More
AbbVie, Harvard partner on $30M emerging virus research
AbbVie and Harvard University announced a $30 million collaborative research alliance to study therapies against emerging viral infections. Read More
Partner Therapeutics begins COVID-19 clinical trial for Leukine
Partner Therapeutics has enrolled the first patient in its iLeukPulm clinical trial, a randomized phase II study of inhaled sargramostim (Leukine) in hospitalized COVID-19 patients with acute hypoxemia. Read More
Carisma, NYU Langone to develop Vpx lentiviral vector
Carisma Therapeutics has entered into a scientific research and licensing agreement with NYU Langone Health to attain exclusive rights to develop and commercialize a Vpx lentiviral vector globally for all indications. Read More
EpiVax licenses COVID-19 vaccine to EVT
EpiVax has licensed its COVID-19 vaccine candidate, EPV-CoV-19, to EpiVax Therapeutics (EVT), formerly known as EpiVax Oncology. Read More
Catalent to support AstraZeneca COVID-19 vaccine manufacturing
Catalent and AstraZeneca have signed an agreement to expand manufacturing support for an adenovirus vector-based COVID-19 vaccine from the University of Oxford. Read More
Harbour BioMed, Vir to develop new therapies
Harbour Biomed and Vir Biotechnology have partnered to research and develop novel immuno-oncology and infectious disease therapies. Read More
Expression Therapeutics develops stem cell lentiviral gene therapy
Expression Therapeutics has developed a potentially curative gene therapy candidate for familial hemophagocytic lymphohistiocytosis type 3. Read More
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Connect
